351 related articles for article (PubMed ID: 27344172)
21. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
22. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
23. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
[TBL] [Abstract][Full Text] [Related]
24. Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Liang P; Shi H; Zhu W; Gui Q; Xu Y; Meng J; Guo X; Gong Z; Chen H
Oncotarget; 2017 Jan; 8(5):7533-7539. PubMed ID: 27893419
[TBL] [Abstract][Full Text] [Related]
25. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Chen CC; Taniguchi T; D'Andrea A
J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219
[TBL] [Abstract][Full Text] [Related]
26. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
27. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
28. Multifaceted resistance of gliomas to temozolomide.
Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
[TBL] [Abstract][Full Text] [Related]
29. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
30. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Wang N; Zhang Q; Ning B; Luo L; Fang Y
Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
[TBL] [Abstract][Full Text] [Related]
31. Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Berte N; Lokan S; Eich M; Kim E; Kaina B
Oncotarget; 2016 Oct; 7(41):67235-67250. PubMed ID: 27626497
[TBL] [Abstract][Full Text] [Related]
32. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
34. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gilbert CA; Daou MC; Moser RP; Ross AH
Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
[TBL] [Abstract][Full Text] [Related]
35. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
[TBL] [Abstract][Full Text] [Related]
36. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
[TBL] [Abstract][Full Text] [Related]
37. Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Lan T; Zhao Z; Qu Y; Zhang M; Wang H; Zhang Z; Zhou W; Fan X; Yu C; Zhan Q; Song Y
Oncotarget; 2016 Aug; 7(34):55555-55571. PubMed ID: 27487130
[TBL] [Abstract][Full Text] [Related]
38. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385
[TBL] [Abstract][Full Text] [Related]
39. The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Lu XY; Cao K; Li QY; Yuan ZC; Lu PS
J Int Med Res; 2012; 40(3):995-1004. PubMed ID: 22906272
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Ohba S; Hirose Y; Kawase T; Sano H
J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
